220 related articles for article (PubMed ID: 14572163)
1. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms.
Nakagami H; Jensen KS; Liao JK
Ann Med; 2003; 35(6):398-403. PubMed ID: 14572163
[TBL] [Abstract][Full Text] [Related]
2. Statins and myocardial hypertrophy.
Nakagami H; Liao JK
Coron Artery Dis; 2004 Aug; 15(5):247-50. PubMed ID: 15238820
[TBL] [Abstract][Full Text] [Related]
3. Statins and the myocardium.
Mital S; Liao JK
Semin Vasc Med; 2004 Nov; 4(4):377-84. PubMed ID: 15861318
[TBL] [Abstract][Full Text] [Related]
4. Impact of HMG CoA reductase inhibition on small GTPases in the heart.
Laufs U; Kilter H; Konkol C; Wassmann S; Böhm M; Nickenig G
Cardiovasc Res; 2002 Mar; 53(4):911-20. PubMed ID: 11922901
[TBL] [Abstract][Full Text] [Related]
5. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
Takemoto M; Node K; Nakagami H; Liao Y; Grimm M; Takemoto Y; Kitakaze M; Liao JK
J Clin Invest; 2001 Nov; 108(10):1429-37. PubMed ID: 11714734
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy for cardiac hypertrophy and heart failure.
Liao JK
J Investig Med; 2004 May; 52(4):248-53. PubMed ID: 15521546
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.
Habibi J; Whaley-Connell A; Qazi MA; Hayden MR; Cooper SA; Tramontano A; Thyfault J; Stump C; Ferrario C; Muniyappa R; Sowers JR
Endocrinology; 2007 May; 148(5):2181-8. PubMed ID: 17317778
[TBL] [Abstract][Full Text] [Related]
8. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Tanaka S; Fukumoto Y; Nochioka K; Minami T; Kudo S; Shiba N; Takai Y; Williams CL; Liao JK; Shimokawa H
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1591-600. PubMed ID: 23640485
[TBL] [Abstract][Full Text] [Related]
9. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy.
Custodis F; Eberl M; Kilter H; Böhm M; Laufs U
Cardiovasc Res; 2006 Jul; 71(2):342-51. PubMed ID: 16698001
[TBL] [Abstract][Full Text] [Related]
10. Rac1-mediated effects of HMG-CoA reductase inhibitors (statins) in cardiovascular disease.
Adam O; Laufs U
Antioxid Redox Signal; 2014 Mar; 20(8):1238-50. PubMed ID: 23919665
[TBL] [Abstract][Full Text] [Related]
11. Differential endothelial hydrogen peroxide signaling via Nox isoforms: Critical roles for Rac1 and modulation by statins.
Waldeck-Weiermair M; Yadav S; Kaynert J; Thulabandu VR; Pandey AK; Spyropoulos F; Covington T; Das AA; Krüger C; Michel T
Redox Biol; 2022 Dec; 58():102539. PubMed ID: 36401888
[TBL] [Abstract][Full Text] [Related]
12. Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase.
Kwok JM; Ma CC; Ma S
Vascul Pharmacol; 2013 Jan; 58(1-2):21-30. PubMed ID: 23085091
[TBL] [Abstract][Full Text] [Related]
13. SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins.
Kudo S; Satoh K; Nogi M; Suzuki K; Sunamura S; Omura J; Kikuchi N; Kurosawa R; Satoh T; Minami T; Ikeda S; Miyata S; Shimokawa H
Hypertension; 2016 May; 67(5):878-89. PubMed ID: 26975711
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
15. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment.
Maack C; Kartes T; Kilter H; Schäfers HJ; Nickenig G; Böhm M; Laufs U
Circulation; 2003 Sep; 108(13):1567-74. PubMed ID: 12963641
[TBL] [Abstract][Full Text] [Related]
16. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits.
Brown JH; Del Re DP; Sussman MA
Circ Res; 2006 Mar; 98(6):730-42. PubMed ID: 16574914
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin inhibits protein isoprenylation in the brain.
Ostrowski SM; Johnson K; Siefert M; Shank S; Sironi L; Wolozin B; Landreth GE; Ziady AG
Neuroscience; 2016 Aug; 329():264-74. PubMed ID: 27180285
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin activates the PPARγ-dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signaling.
Zou C; Qi H; Liu ZH; Han L; Zhao C; Yang X
Tex Heart Inst J; 2013; 40(2):140-7. PubMed ID: 23678211
[TBL] [Abstract][Full Text] [Related]
19. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase.
Park HJ; Galper JB
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11525-30. PubMed ID: 10500210
[TBL] [Abstract][Full Text] [Related]
20. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin.
Takeda N; Kondo M; Ito S; Ito Y; Shimokata K; Kume H
Am J Respir Cell Mol Biol; 2006 Dec; 35(6):722-9. PubMed ID: 16858009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
